Abstract Purpose: To evaluate the safety and efficacy of a next-generation balloon-expandable stent-graft for the treatment of arterial occlusive disease in patients with de novo or restenotic lesions in the common and/or external iliac arteries. Methods: A prospective, multicenter, single-arm safety and efficacy study (ClinicalTrials.gov identifier: NCT02080871) of the VBX Stent Graft for treatment of de novo or restenotic lesions in the iliac arteries was conducted under an Investigational Device Exemption at 26 US sites and 1 New Zealand center. The study eligibility criteria were established with the aim of enrolling more "real-world" patients compared with previous iliac stent studies supporting Food and Drug Administration approval. The study enrolled 134 patients (mean age 66±9.5 years; 79 men) with 213 iliac lesions. Threequarters of the population (101, 75.4%) had Rutherford category 3 ischemia, and 43 (32.1%) patients presented with TASC II C/D lesions. The primary endpoint was a composite of device-or procedure-related death within 30 days, myocardial infarction within 30 days, target lesion revascularization (TLR) within 9 months, and amputation above the metatarsals in the treated leg within 9 months. Results: In all, 234 devices were implanted in 213 lesions with 100% technical success; 57 (42.5%) patients received kissing stents at the aortic bifurcation. No devices exhibited a discernable change in length after final deployment as determined by independent core laboratory quantitative angiographic analysis. At 9 months, 3 (2.3%) of 132 patients (1 lost to follow-up, 1 unrelated death) experienced a major adverse event (3 TLRs) related to the primary endpoint. At 9 months, there were no device-related serious adverse events or unanticipated adverse device effects.
Introduction
Approximately one-third of atherosclerotic peripheral artery disease involves aortoiliac occlusive disease (AIOD). 1 Stenting of patients presenting with less advanced AIOD [TransAtlantic Inter-Society Consensus II (TASC II) A and B lesions] is an established, durable treatment approach for relieving claudication and related symptoms. A Class I treatment effect supports the American College of Cardiology/ American Heart Association's recommendation for endovascular treatment of claudication and the conclusion that stenting is effective as primary therapy for iliac artery stenoses and occlusions. 2 Current TASC II consensus guidelines recommend surgery for more severe TASC II C/D AIOD, 3, 4 although multiple consensus and practice guidelines now generally endorse an endovascular-first strategy for these lesions in experienced endovascular centers. [5] [6] [7] [8] Stent-grafts have been approved by the Food and Drug Administration (FDA) for treating AIOD for more than a decade, and corresponding studies supporting their approval have typically evolved with time to reflect changes in clinical best practices as well as device capabilities due to improved stent technology. Advancement in clinical practice/standard of care treatment of AIOD has progressed from a surgeryfirst strategy toward an endovascular-first approach, with endovascular treatment of complex AIOD being promoted only recently. Current endovascular AIOD treatment often involves primary or direct stenting 5, 9 and utilization of kissing stents for disease directly adjacent to or involving the aortic bifurcation. 1, 5 Numerous studies have shown favorable outcomes for stent-graft treatment of complex AIOD, [9] [10] [11] [12] [13] [14] [15] [16] [17] and a prospective, multicenter, randomized trial (COBEST: COvered versus Balloon Expandable Stent Trial) has demonstrated a statistically significant clinical benefit for stent-grafts vs bare metal stents in complex TASC II C/D lesions. 14, 18 Results of the double-blind, randomized DISCOVER trial (Dutch Iliac Stent trial: COVERed balloon-expandable vs uncovered balloon-expandable stents in the common iliac artery) are awaited to see if the COBEST study results are confirmed. 19 Stent-grafts possess unique advantages over bare metal stents, including plaque exclusion and prevention of instent neointimal hyperplasia, improved blood hemodynamics via a new flow lumen, and decreased risk of complications resulting from distal embolization, perforation, rupture, or dissection. 1, 9, 14, 16 The Society for Vascular Surgery recommends stent-graft placement for treatment of AIOD in instances of severe calcification at risk of vessel rupture. 5 Commercially available balloon-expandable stents (both bare metal and stent-graft) have been proven safe and effective for treating AIOD and thus are routinely used. However, the primary drawbacks of the current technologies include stent rigidity, both on-catheter and once implanted, as well as stent dislodgement from the delivery system leading to complications. [20] [21] [22] [23] The VBX FLEX clinical study sought to evaluate a new stent-graft using a treatment methodology and patient population more aligned with current standard of care. As a result, the study enrolled patients with tortuous iliac arteries, severe lesion calcification, total occlusions, and the need for direct stenting and/or kissing stents at the aortic bifurcation. Specifically, the study design allowed more challenging pathology than that seen in historical iliac stent studies supporting FDA approval.
Methods

Study Device
The GORE VIABAHN VBX Balloon Expandable Endoprosthesis (referred to as VBX Stent Graft; W. L. Gore & Associates, Flagstaff, AZ, USA; Figure 1 ) is composed of independent stainless steel rings connected via fluoropolymer graft material, making it the only peripheral stent-graft lacking longitudinal stent struts. Ring spacing and orientation (peak-to-valley) maximize device flexibility on-and off-catheter yet minimize graft-only surface area, while providing critical scaffolding. Additionally, the graft material is capable of expansion to large diameters without compromising its integrity or durability. Stent ring geometry combined with 316L stainless steel are the unique elements, which preclinical studies have shown as responsible for the device's high radial strength, minimal foreshortening, and precise placement. A thin fluoropolymer/elastomer film covers the percutaneous balloon on the delivery catheter to ensure stent-graft retention during tracking and balloon inflation. Additionally, heparin is covalently bonded to the device luminal surface (CBAS Heparin Surface). Configurations available for use in the study are listed in Table 1 (all 0.035-inch over-the-wire configurations available on 80 and 135 cm catheter lengths).
Study Design and Patient Enrollment
The VBX FLEX study was a prospective, multicenter, single-arm clinical trial conducted under an Investigational Device Exemption at 26 hospitals in the United States and 1 in Auckland, New Zealand, to evaluate the safety and efficacy of the VBX Stent Graft for treatment of de novo or restenotic lesions in the iliac arteries. The local or centralized institutional review board for US hospitals and the ethics committee for the New Zealand hospital approved the study protocol and informed consent form, which was signed by all patients prior to study enrollment.
This study was conducted in accordance with the Declaration of Helsinki (59th WMA General Assembly, Seoul, Republic of Korea, October 2008). An Independent Data Safety Monitoring Board (DSMB) was responsible for safeguarding the interests of study patients, assessing the safety of the interventions, and monitoring the overall conduct of the clinical study. Additionally, the DSMB reviewed information pertaining to enrolled patients to determine if all eligibility criteria (Table 2) were met. The severity of each adverse event was determined by the site investigator based on the International Organization for Standardization (ISO) 14155:2011 definition of serious and nonserious adverse events. An independent Clinical Events Committee (CEC) was responsible for adverse event adjudication and determining whether the event met any of the prespecified components of the composite primary endpoint. Any serious adverse events (SAE) or events that were potentially device-related were reviewed by the CEC. The independent core laboratories VasCore (Boston, MA, USA) and Yale Angiographic Core Laboratory (New Haven, CT, USA) conducted ultrasound and angiography analyses, respectively. The trial was registered on the National Institutes of Health website (ClinicalTrials.gov; identifier NCT02080871).
Between December 17, 2013 , and August 12, 2015, 134 patients (mean age 66±9.5 years; 79 men) meeting all 
Study Procedures
Vascular access, anticoagulation, and introduction of guidewires/catheters were conducted using each institution's standard of care for iliac endovascular procedures. Baseline aortoiliac angiography with runoff and 2 orthogonal views of the target lesion were required to assess target lesion characteristics and to determine final patient eligibility. Predilation of the target lesion was at physician discretion. After the target lesion was successfully crossed with a 0.035-inch wire, the VBX Stent Graft was advanced and implanted according to the instructions for use in alignment with standard of care for iliac stenting. Kissing stent-grafts were placed when lesions involved the aortic bifurcation and when proximal common iliac artery (CIA) disease could not be adequately managed without extending into the aortic bifurcation. 
Study Outcomes
The primary study endpoint was a composite of major adverse events (MAEs) defined as device-or procedurerelated death within 30 days, myocardial infarction (MI) within 30 days, target lesion revascularization (TLR) within 9 months, and amputation above the metatarsals in the treated leg resulting from a vascular event within 9 months. The 9-month primary endpoint was selected in order to align with previous iliac stenting studies supporting FDA premarket approval applications (the majority being 9 month), thereby enabling a prospective performance goal to be derived from these previous study outcomes. Secondary study outcomes were acute procedure success (≤30% residual stenosis prior to procedure completion and no device-or procedure-related SAEs before discharge), 30-day clinical success (improvement of at least 1 Rutherford category at the 30-day visit and no device-or procedure-related SAEs), primary patency (evidence of blood flow through the study device determined by ultrasound or angiography and without reintervention), assisted primary patency, secondary patency, freedom from TLR, freedom from clinically driven TLR (increase in Rutherford category prior to TLR), freedom from target vessel revascularization (TVR), freedom from clinically driven TVR, change in Rutherford category, change in ABI, and change in functional status (based on patient questionnaires). Additional analyses included technical success (successful device delivery and ≤30% residual stenosis) and change in device length (from mounted to final implanted). Analysis of change in device length was conducted by an independent core laboratory using quantitative angiographic measurements comparing the predeployed length to the final implanted length (after any postdilation, if conducted).
Statistical Analysis
Continuous data are presented as the means ± standard deviation or median (interquartile range, IQR); categorical data are given as the counts (percentage). Time-to-event outcomes were analyzed using a log-rank test. For the primary outcome, a sample size of 135 patients obtains >90% power to statistically show that the probability of a patient receiving the study device will experience a MAE is <17% when ≤12% of the patients are lost to follow-up prior to the 9-month visit. This calculation assumes usage of a 1-sided binomial exact test and a type 1 error rate of 5%. For power calculations, the probability of having a MAE was assumed to be 8%. The sample size calculation was performed using PASS software (version 2008; Power Analysis and Sample Size Software, NCSS, LLC, Kaysville, UT, USA), while the Kaplan-Meier estimates were generated using SAS software (version 9.3; SAS Institute, Inc, Cary, NC, USA).
Results
In all, 234 stent-grafts were implanted in 213 lesions (Table  4) ; half of all patients received stent-grafts bilaterally, mostly for kissing stent placement at the aortic bifurcation (42.5% of total cohort). Twenty-four (17.9%) patients received at least 1 study device delivered from a contralateral approach (Figure 2A ). The stent-graft was implanted in 31 (23.4%) external iliac arteries (EIA) in 201 treated limbs, including associated CIA placement. All devices were successfully delivered (100% technical success), conforming well to the native vessel even when tortuous ( Figure 2B ). The overall median change in device length (predeployed to final implanted) was −0.05 mm (IQR −0.30, 0.09). Within the ±5-mm accuracy of the measurement, none of the 164 evaluable devices showed a change in length. Acute procedure success was achieved in 130 (97.0%) patients; the 4 exceptions were patients who experienced 5 procedure-related SAEs prior to discharge (common femoral pseudoaneurysm, groin hematoma, loss of limb pulse due to closure device, hypovolemic shock, and altered mental status changes with underlying vascular dementia). Four of the procedure-related SAEs resolved with treatment; the "altered mental status" SAE required no treatment and resolved on day 2. The SAE access site complication rate (per access site) was 1.8% (4/217). Thirty-day clinical success was 90.8% (108/119) due to 5 patients experiencing procedure-related SAEs (the 5 events described above in 4 patients plus another case of severe claudication that resolved with treatment of an outflow vessel) and absence of Rutherford improvement in 6 patients. Compliance with the recommended anticoagulation therapy regimen at 1 and 9 months was 85.1% and 62.1%, respectively.
Two patients were censored from the primary endpoint analysis due to follow-up loss and death, the latter due to cardiac arrest on day 187 (not device-or procedure-related). There were no device-related SAEs or unanticipated adverse device effects through 9 months (Table 5 ). The 9-month composite primary endpoint in the 132 evaluable patients was 2.3% (3 TLRs), well below the 17% performance goal (p<0.001). The 9-month composite primary endpoint for the 57 patients receiving kissing stents was similar [3.5% (2 TLRs); p=0.002].
Kaplan-Meier estimates of the secondary outcomes at 1 and 9 months are reported in Table 6 . All secondary outcomes related to patency and freedom from TLR and TVR measures ranged from 99.2% to 100.0% and 96.7% to 99.5% at the respective time points, with minimal difference on a per-lesion vs per-patient basis. At 30-day followup, 1 subject lacked evidence of blood flow through the treated segment but revascularization was not attempted, resulting in 100% freedom from TLR yet 99.2% patency. The 9-month per-lesion primary patency for the full cohort was 96.9% ( Figure 3A) , with primary patency in TASC II A/B vs C/D lesions of 97.4% and 95.3%, respectively (p=0.461; Figure 3B ). EIA primary patency was 97.4% at 9 months. Compared with baseline, no patients had a worsened Rutherford category assessment at 9 months, whereas 6/112 (5.4%) maintained and 106/112 (94.6%) improved ( Figure 4A ). Mean ABI increased from 0.77±0.22 to 0.97±0.18 at 9 months (p<0.001) and WIQ scores improved overall ( Figure 4B ).
Discussion
Iliac artery stenting has been largely successful, with good results over long-term follow-up, 24 particularly when stentgrafts have been used. 25 A recent first-in-human evaluation of the VBX Stent Graft reported a positive experience, 26 corroborated by the current study with 100% technical success, 97% acute procedure success, and a TLR rate of 2.3% at 9 months.
Unlike other iliac stenting trials supporting FDA approval, this study was designed to reflect current practice. As a result, eligibility criteria permitted (without limitations) inclusion of patients with tortuous iliac arteries, severe lesion calcification, total occlusions, and direct stenting (predilation optional) and/or kissing stent treatment at the aortic bifurcation. Other iliac stent pivotal studies have placed restrictions or limitations on these variables. [27] [28] [29] [30] [31] Additional decisions left to the judgment of the study interventionist included the use of reentry devices, postdilation, and the determination of adequate ipsilateral outflow.
This study sought to incorporate challenging cases, with nearly a third of all patients having TASC II C/D lesions. A recent study showed that treatment of long segment CIA/ EIA stenoses with bare metal stents was a negative predictor of patency. 32 Therefore, the prevailing thought in TASC II D lesions is to use stent-grafts, which has resulted in improved outcomes in difficult lesions. 14, 18, 33 The 96.9% VBX FLEX 9-month primary patency, in particular the subanalysis of TASC II C/D lesions (95.3%), was at the very least comparable to the best series available. 21, 32 Furthermore, more than a third of patients received kissing stents, which are considered standard of care when proximal CIA occlusive disease involves the aortic bifurcation. 5 Typically, this anatomy/disease is more challenging and therefore poorer outcomes are expected. 21 Similar composite MAE rates at 9 months were noted for the kissing stent subgroup and the overall study group. Additionally, the kissing stent MAE percentage was considered low relative to both the performance goal and the literature. 16 It is well known that EIAs are generally more tortuous, which is likely why many interventionists generally prefer self-expanding stents in this location. The EIA is also more dynamic/mobile compared to the CIA and correspondingly has demonstrated lower patency. 6, 19 The longitudinal compression seen in this location can be detrimental to balloonexpandable stents. However, due to its innovative discrete steel ring structure, the VBX Stent Graft is able to amply accommodate this motion, as demonstrated by the favorable 9-month primary patency in the EIA. There were several remarkable outcomes and observations that are likely attributable to the unconventional device design. The device length did not change when comparing the predeployed vs implanted device lengths. This is likely due to the fluoropolymer-connected stent rings and/or the balloon cover on the delivery system, both of which possess some longitudinal mobility to accommodate geometrical changes during balloon inflation. Additionally, all devices were successfully delivered, with no device dislodgement even in contralateral deliveries, likely owing to the combination of on-catheter device flexibility and its interaction with the balloon cover. Finally, in all instances the residual stenosis was ≤30%, thereby validating the device design and specifically the ample radial strength demonstrated even in challenging lesions. Altogether, multiple clinical benefits were observed, which can be rationally explained by specific design elements.
One of the practical considerations with this device is the need in certain instances for a larger sheath than other balloon-expandable stents on the market (configurations are compatible with either 7-F or 8-F introducer sheaths). Historically, access site complication rates have been 10.5% for women and 5% for men, 34 but in modern interventions it has been shown that closure devices are a negative predictor for access site complications. 35 A major access site-related complication rate of ~2% to 3% has been frequently reported, 36, 37 which is acceptable according to the Society of Interventional Radiology quality improvement guidelines. 37 The incidence of access site complications in this trial was acceptably low and comparable to these commonly reported rates.
Limitations
Although at a high level the study design is similar to other iliac stent studies, nuances complicate direct comparisons of results. As discussed earlier, eligibility criteria allowed for a more challenging patient population due to the desire to mirror contemporary clinical practice. Additionally, the specific outcomes often differ slightly, along with definitions such as all-TLR vs clinically driven TLR. 27, 29 Furthermore, the reporting of study results is limited to 9 months with longer term follow-up still pending. Additionally, the study did not employ a randomized design to directly compare outcomes to a control iliac stent.
Conclusion
This study successfully demonstrated the efficacy and safety of the study device in treating AIOD. The study device performed equally well in disadvantaged circumstances as it did in straightforward lesions. This speaks to its attributes, such as trackability, radial strength, conformability, and stent retention. Although relatively short term, the favorable 9-month primary patency, in conjunction with the liberal inclusion/exclusion criteria and unique product attributes, suggest that the GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be a valuable stent-graft in the management of AIOD.
